Parasitic infections affect billions of people worldwide, particularly in tropical and subtropical regions, and cause immense morbidity and mortality. Antiparasitic drugs target protozoa (single-celled organisms) and helminths (worms) through diverse mechanisms that exploit differences between parasite and human biochemistry.
What Are Antiparasitic Drugs?
Antiparasitic agents are classified by the type of parasite they target and their mechanism of action. Treatment often requires balancing efficacy against toxicity, and resistance is a growing concern particularly in malaria and intestinal helminths.
Drug Classes and Mechanisms
Antimalarials include several classes targeting different life cycle stages of Plasmodium species. Chloroquine concentrates in parasitized erythrocytes and inhibits heme polymerase, killing the intraerythrocytic stages. Artemisinin combination therapies (ACTs), including artemether-lumefantrine, are first-line for uncomplicated falciparum malaria. Artemisinins produce rapid parasite clearance through free radical-mediated damage. Atovaquone-proguanil inhibits mitochondrial electron transport and dihydrofolate reductase. Mefloquine disrupts parasite membranes. Quinine, a cinchona alkaloid, is used for severe malaria typically in combination with intravenous artesunate.
Anti-protozoal agents treat a range of infections. Metronidazole and tinidazole are nitroimidazoles that cause DNA damage in anaerobic organisms and microaerophilic parasites including Giardia, Entamoeba, and Trichomonas. Nitazoxanide has broad anti-protozoal activity including Cryptosporidium. Pentamidine is used for Pneumocystis jirovecii pneumonia in HIV, though its use is limited by substantial toxicity including hypoglycemia, nephrotoxicity, and cardiac arrhythmias.
Anthelmintics target helminth infections. Albendazole and mebendazole are benzimidazoles that bind tubulin, inhibiting microtubule formation and glucose uptake. Albendazole is effective for tissue helminths including hydatid disease and neurocysticercosis. Ivermectin activates glutamate-gated chloride channels in nematodes and arthropods, causing paralysis and death. It is used for onchocerciasis, strongyloidiasis, and scabies. Praziquantel increases calcium permeability in schistosome tegument, causing muscle contraction and paralysis, and is the drug of choice for all schistosome species and many cestode infections.
Therapeutic Uses
Uncomplicated malaria is treated with ACTs based on local resistance patterns. P. vivax requires additional primaquine for hypnozoite eradication. Severe malaria requires intravenous artesunate. Intestinal protozoal infections respond to metronidazole or tinidazole. Soil-transmitted helminths are treated with single-dose albendazole or mebendazole. Mass drug administration programs in endemic areas reduce transmission of lymphatic filariasis, onchocerciasis, and schistosomiasis.
Adverse Effects
Chloroquine causes pruritus and retinopathy with prolonged use. Artemisinin derivatives are well tolerated but rare hypersensitivity occurs. Metronidazole causes metallic taste, nausea, and disulfiram-like reactions with alcohol. Albendazole may cause hepatotoxicity and bone marrow suppression with prolonged courses. Ivermectin causes Mazzotti reactions in onchocerciasis due to rapid killing of microfilariae.
Key Clinical Considerations
Antimalarial resistance, particularly artemisinin partial resistance in Southeast Asia and increasingly in Africa, threatens global malaria control. Albendazole and mebendazole are contraindicated in early pregnancy. Ivermectin should not be used in patients with Loa loa coinfection due to risk of severe encephalopathy. Prophylactic antimalarials should be selected based on travel destination, resistance patterns, and patient factors.
Conclusion
Antiparasitic drugs remain essential for controlling parasitic diseases that disproportionately affect resource-limited settings. The threat of drug resistance, especially in malaria, underscores the need for continued drug development and resistance surveillance.
